GlassScriptPhysician profile
Timothy J Izzo
NPI 1720152846
$124,093.36
in general payments reported to CMS, 2019-2025
51 companies · $4,748 in 2025
The $4,748 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,121 · 2020: $449 · 2021: $1,294 · 2022: $33K · 2023: $50K · 2024: $25K · 2025: $4,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Food and Beverage: $8,747 · Travel and Lodging: $7,262 · Consulting Fee: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,900.00 |
| Food and Beverage | $8,747.22 |
| Travel and Lodging | $7,261.77 |
| Consulting Fee | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $113,074.45 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,775.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,534.33 | 2019-2025 | |
| Pfizer INC. | $1,069.66 | 2019-2025 | |
| Amgen INC. | $988.05 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $804.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $492.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.25 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $452.72 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $251.78 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.47 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $225.47 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $222.54 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $187.16 | 2021-2025 | |
| Sanofi Pasteur INC. | $172.25 | 2019-2024 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $160.64 | 2019-2022 | |
| Amarin Pharma, INC. | $144.49 | 2019-2022 | |
| Radius Health, INC. | $135.67 | 2019-2025 | Tymlos |
| Grifols USA, LLC | $134.15 | 2024 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $109.77 | 2025 | Auvelity |
| Exact Sciences Corporation | $109.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $105.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $95.36 | 2021-2025 | Austedo Xr, Ajovy, Airduo Digihaler |
| Kowa Pharmaceuticals America, INC. | $91.72 | 2022-2023 | Livalo, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $89.19 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $86.69 | 2021 | |
| Averitas Pharma INC. | $83.30 | 2023-2024 | Qutenza |
| Dexcom, INC. | $82.73 | 2021-2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $60.28 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.31 | 2019 | |
| Mylan Specialty L.P. | $50.11 | 2019-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $48.15 | 2021-2024 | Eliquis |
| Inspire Medical Systems, INC. | $47.12 | 2023 | Inspire |
| Viatris Specialty LLC | $46.48 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $45.41 | 2019 | |
| Astellas Pharma US INC | $40.50 | 2021-2024 | Veozah |
| Halozyme INC | $39.74 | 2023 | |
| Neurocrine Biosciences, INC. | $38.14 | 2025 | |
| Abbott Laboratories | $35.83 | 2025 | Freestyle Libre 3, Id Now Instrument |
| Baxter Healthcare | $30.71 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Antares Pharma, INC. | $19.90 | 2024 | Xyosted |
| Paratek Pharmaceuticals, INC. | $18.91 | 2022 | |
| Eisai INC. | $17.07 | 2025 | |
| Arbor Pharmaceuticals, INC. | $15.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.69 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $14.60 | 2019 | Xyosted |
| Idorsia Pharmaceuticals US INC | $14.28 | 2024 | Quviviq |
| Phadia US INC. | $14.07 | 2025 | Immunocap |
| Tolmar, INC. | $14.06 | 2024 | |
| Grt US Holding, INC. | $13.29 | 2022 | |
| Gilead Sciences, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Izzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.